Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212 489 2100

Fax: 212 489 2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, Queensbury, United States

topstockalerts Jun. 23 at 9:21 PM

$DCTH this move has a surprisingly mature feel to it.

0 · Reply

Value1008 Jun. 23 at 4:05 PM

$DCTH - early yesterday i wondered if the HFT trading bots would take this down for another test of support at the 20dma, as happened on June 11 before rebounding, and sure enough the stock was manipulated down near to that 20dma by yesterday's close. This morning it bounced strongly off that support line and now we see a powerful breakout to the upside. Let's see in coming days where the new support line is. In any case, fundamentals look strong for the longer term investment.

0 · Reply

alexpitti Jun. 22 at 5:12 PM

did you guys see another hospital hit 100 hepzato treatments? $DCTH

1 · Reply

Ratman44 Jun. 18 at 8:00 PM

$DCTH pretty sure every day they update the website with a new center it goes down.

0 · Reply

mar99 Jun. 18 at 4:28 PM

$DCTH Canaccord reiterated their Buy rating on Dcth. Price target 21.

0 · Reply

alexpitti Jun. 18 at 3:30 PM

$DCTH is columbia an ai data center? If not we are screwed

0 · Reply

pufferfishcapital Jun. 18 at 2:36 PM

$DCTH Columbia University Medical Center just added as 30th active center

0 · Reply

alexpitti Jun. 17 at 7:52 PM

the fed ruined our winning day. wow $MIST $STXS $DCTH $ABEO

2 · Reply

alexpitti Jun. 17 at 3:26 PM

$DCTH there is a major battle for delcath at $12 for whatever reason

0 · Reply

mar99 Jun. 17 at 3:14 PM

$DCTH Sticking to its normal daily routine today. Run up over 12 followed by selling taking it quickly back below 12. Seems to be the case most every day now. I guess they aren’t ready to let it close over 12 yet. Hopefully that’s coming.

0 · Reply

Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

May 26, 2026, 4:01 PM EDT - 4 weeks ago

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

May 15, 2026, 4:01 PM EDT - 5 weeks ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-07T14:11:04.000Z - 6 weeks ago

Delcath Systems presents new data on M-PHP at ESMO

2026-05-07T13:35:47.000Z - 6 weeks ago

Delcath Systems reports Q1 EPS (3c), consensus (9c)

2026-05-07T13:34:32.000Z - 6 weeks ago

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Delcath Systems Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Delcath Systems Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Delcath Systems Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Apr 23, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems to Host First Quarter 2026 Earnings Call

Apr 6, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

2026-04-02T14:44:15.000Z - 2 months ago

Delcath Systems management to meet with Craig Hallum

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Delcath Systems Proxy statement: Proxy filing

Apr 1, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

2026-03-03T13:43:26.000Z - 4 months ago

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Mar 3, 2026, 8:00 AM EST - 4 months ago

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

2026-02-26T18:26:15.000Z - 4 months ago

Delcath Systems price target lowered to $27 from $29 at Clear Street

2026-02-26T13:33:50.000Z - 4 months ago

Delcath Systems reports Q4 EPS (5c), consensus (3c)

2026-02-26T13:33:07.000Z - 4 months ago

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 8:00 AM EST - 4 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Jan 27, 2026, 8:05 AM EST - 5 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2026-01-09T15:30:16.000Z - 5 months ago

Delcath Systems price target raised to $29 from $28 at Clear Street

2026-01-09T13:15:29.000Z - 5 months ago

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

Jan 9, 2026, 8:05 AM EST - 5 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

2025-12-31T13:15:08.000Z - 6 months ago

Delcath Systems publishes results from subgroup analyses of FOCUS study

Dec 31, 2025, 8:00 AM EST - 6 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

2025-12-03T21:05:29.000Z - 7 months ago

Delcath Systems announces publication of CHEMOSAT study

Dec 3, 2025, 4:01 PM EST - 7 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

2025-11-20T21:05:49.000Z - 7 months ago

Delcath Systems authorizes $25M buyback program

Nov 20, 2025, 4:01 PM EST - 7 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

2025-11-18T14:38:40.000Z - 7 months ago

Delcath Systems publishes review of Hepzato Kit

Nov 18, 2025, 8:00 AM EST - 7 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

2025-11-13T14:21:28.000Z - 7 months ago

Delcath announces publication supporting early use of liver-directed therapy

Nov 13, 2025, 8:30 AM EST - 7 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 6, 2025, 4:01 PM EST - 8 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

2025-10-21T13:05:37.000Z - 8 months ago

Delcath Systems price target lowered to $20 from $24 at Craig-Hallum

Oct 21, 2025, 8:30 AM EDT - 8 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

2025-10-20T16:00:49.000Z - 8 months ago

Clear Street ups Delcath target, sees opportunity on selloff

Oct 20, 2025, 8:45 AM EDT - 8 months ago

Delcath Systems Transcript: Study Result

Oct 20, 2025, 8:45 AM EDT - 8 months ago

Delcath Systems Press release: Study Result

Oct 20, 2025, 7:00 AM EDT - 8 months ago

Delcath Systems Slides: Corporate Presentation

Oct 18, 2025, 4:15 PM EDT - 8 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:13 PM EDT - 8 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Sep 22, 2025, 4:01 PM EDT - 9 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 10, 2025, 11:00 AM EDT - 10 months ago

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 23, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

May 22, 2025, 10:00 AM EDT - 1 year ago

Delcath Systems Slides: Investor Presentation

May 22, 2025, 7:00 AM EDT - 1 year ago

Delcath Systems Issues Full Year 2025 Guidance

May 15, 2025, 4:30 PM EDT - 1 year ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 1 year ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q1 2025

May 8, 2025, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q3 2024

Nov 8, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

topstockalerts Jun. 23 at 9:21 PM

$DCTH this move has a surprisingly mature feel to it.

0 · Reply

Value1008 Jun. 23 at 4:05 PM

0 · Reply

alexpitti Jun. 22 at 5:12 PM

did you guys see another hospital hit 100 hepzato treatments? $DCTH

1 · Reply

Ratman44 Jun. 18 at 8:00 PM

$DCTH pretty sure every day they update the website with a new center it goes down.

0 · Reply

mar99 Jun. 18 at 4:28 PM

$DCTH Canaccord reiterated their Buy rating on Dcth. Price target 21.

0 · Reply

alexpitti Jun. 18 at 3:30 PM

$DCTH is columbia an ai data center? If not we are screwed

0 · Reply

pufferfishcapital Jun. 18 at 2:36 PM

$DCTH Columbia University Medical Center just added as 30th active center

0 · Reply

alexpitti Jun. 17 at 7:52 PM

the fed ruined our winning day. wow $MIST $STXS $DCTH $ABEO

2 · Reply

alexpitti Jun. 17 at 3:26 PM

$DCTH there is a major battle for delcath at $12 for whatever reason

0 · Reply

mar99 Jun. 17 at 3:14 PM

0 · Reply

alexpitti Jun. 17 at 4:06 AM

delcath's short interest has fallen to 9%. the shorts have left the building. i remember when we used to be around 13% $DCTH

1 · Reply

alexpitti Jun. 17 at 2:43 AM

we still need to wait potentially 1 more year before delcath gets coverage for chemosat in the uk. there was a change in the rules, so they needed to resubmit. hopefully, if everything goes well they can get coverage in 2028 $DCTH

0 · Reply

LudwigVanBeethoven Jun. 16 at 11:04 PM

$DCTH lol, 2019 of course

0 · Reply

LudwigVanBeethoven Jun. 16 at 11:03 PM

$DCTH April to Today .. starts to make a clear trend for a real run? Imagine just going back to 2023 and further :))

0 · Reply

Value1008 Jun. 16 at 7:07 PM

$DCTH Even though the stock has been selling off a lot on intraday trading (which seems like very weak trading action and is disappointing for those of us who think it should already be trading well above $12), DCTH continues to show some afternoon buying strength. Presently in the $11.70S, It could easily close at $11.80 or higher, which would be the highest close since last October., so the chart is still showing strength. Having said that, I'll also say that the frequent daily morning higher jumps, followed by mid-morning weakness and re-traces, make me wish I had the time to day-trade and swing-trade this stock!

2 · Reply

alexpitti Jun. 15 at 11:00 PM

if delcath just stays where it's at for the next month, it will hit a 52 week high by default once that decline early last summer rolls off. think about that lol $DCTH

0 · Reply

mar99 Jun. 15 at 2:05 PM

$DCTH Sure would be nice to see a close over 12. We haven’t seen that since last summer. And hopefully a lot more to come after 12.

0 · Reply

FrankZA Jun. 15 at 2:04 PM

$DCTH Moffit has performed 100 Hepzato treatments. We need more centers like Moffit especially when we are still very much behind with the pace of new centers…

0 · Reply

capitalthinktank Jun. 15 at 1:38 PM

$DCTH Bullish setup playing out perfectly. 3-wave pullback completed right at the 0.618 Fib and 200-day MA. Just broke out of the bullish descending wedge and flipped the 50-day MA into solid support. Wave 3 is officially moving now, backed by that massive earnings smash last month. Current: $11 Wave 3 Target: $34

1 · Reply

alexpitti Jun. 15 at 1:18 PM

$DCTH bro sold delcath because of a war with iran and ai??? delcath might have the least to do with either of those things. i'm sorry this is absurd

1 · Reply

actuallysam Jun. 15 at 11:14 AM

$DCTH I have sold down a fair amount over this war and AI bubble and thinking company is not all that undervalued, but then I am back to thinking in next 12 to 24 months it is possible to reach $2 billion market cap if next year does $150 million revenue, market takes to biotech, and speculators heat up on phase 2. Also possible buyout.

0 · Reply

Value1008 Jun. 11 at 9:04 PM

$DCTH - Highest close since last mid-Oct.

0 · Reply

Market Cap	397.35M
Revenue (ttm)	85.23M
Net Income (ttm)	2.70M
EPS (ttm)	N/A
PE Ratio	1,169.00
Forward PE	N/A
Profit Margin	3.17%
Debt to Equity Ratio	0.00

Volume	613,200
Avg Vol	470,776
Day's Range	N/A - N/A
Shares Out	34.52M
Stochastic %K	94%
Beta	0.54
Analysts	Strong Sell
Price Target	$21.67